Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.

Détails

ID Serval
serval:BIB_4D945AED0689
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.
Périodique
Journal of immunotherapy
Auteur(s)
Lienard D., Avril M.F., Le Gal F.A., Baumgaertner P., Vermeulen W., Blom A., Geldhof C., Rimoldi D., Pagliusi S., Romero P., Dietrich P.Y., Corvaia N., Speiser D.E.
ISSN
1524-9557
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
32
Numéro
8
Pages
875-883
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
Toll-like receptor ligands are potentially useful adjuvants for the development of clinical T cell vaccination. Here we investigated the novel Toll-like receptor2 ligand P40, the outer membrane protein A derived from Klebsiella pneumoniae. Seventeen human leukocyte antigen-A*0201 positive stage III/IV melanoma patients were vaccinated with P40 and Melan-A/Mart-1 peptide subcutaneously in monthly intervals. Adverse reactions were mild-to-moderate. Fourteen patients received at least 8 vaccinations and were thus evaluable for clinical tumor and immune responses. Seven patients experienced progressive disease, whereas 2 patients had stable disease throughout the trial period, 1 of them with regression of multiple skin metastases. The remaining 5 patients had no measurable disease. Melan-A/Mart-1 specific CD8 T cells were analyzed ex vivo, with positive results in 6 of 14 evaluable patients. Increased percentages of T cells were found in three patients, memory/effector T cell differentiation in 4 patients, and a positive interferon-gamma Elispot assay in 1 patient. Antibody responses to P40 were observed in all patients. We conclude that vaccination with peptide and P40 was feasible and induced ex vivo detectable tumor antigen specific T cell responses in 6 of 14 patients with advanced melanoma.
Pubmed
Web of science
Création de la notice
15/01/2010 14:58
Dernière modification de la notice
20/08/2019 14:02
Données d'usage